DRD2: dopamine receptor D2
1 protein, 84 patents, 122 drugs, 2,309 trials, 7,939 NIH grants and 16,048 papers.
Gene 7
Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.
Proteins 1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in | Source |
|---|---|---|---|---|---|
| P14416 | Dopamine receptor D2 | 443 | 11 | Ensembl, GeneID, HGNC | UniProt |
Patents 84
Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4777830 A1 | 2026-07-22 | 17 | P14416 | Espacenet |
| JP 2026016502 A | 2026-02-03 | 1 | P14416 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44195 | P14416 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44198 | P14416 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8050 | P14416 | Espacenet |
| JP 2025534434 A | 2025-10-15 | 165 | P14416 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1319 | P14416 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1319 | P14416 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 8050 | P14416 | Espacenet |
| JP 2025516139 A | 2025-05-27 | 2 | P14416 | Espacenet |
Drugs 122
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACETOPHENAZINE | CHEMBL1085 | Dopamine D2 receptor antagonist | ANTAGONIST | ChEMBL |
| ACETOPHENAZINE MALEATE | CHEMBL2360079 | Dopamine D2 receptor antagonist | ANTAGONIST | ChEMBL |
| ADOPRAZINE | CHEMBL221692 | Dopamine D2 receptor antagonist | ANTAGONIST | ChEMBL |
| ALIZAPRIDE | CHEMBL290194 | Dopamine D2 receptor antagonist | ANTAGONIST | ChEMBL |
| AMINEPTINE | CHEMBL418995 | Dopamine D1 and D2 receptor antagonist | ANTAGONIST | ChEMBL |
| AMISULPRIDE | CHEMBL243712 | Dopamine receptors; D2 & D3 antagonist | ANTAGONIST | ChEMBL |
| AMOXAPINE | CHEMBL1113 | Dopamine receptor antagonist | ANTAGONIST | ChEMBL |
| APLINDORE | CHEMBL2110659 | Dopamine D2 receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| APLINDORE FUMARATE | CHEMBL2104864 | Dopamine D2 receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| APOMORPHINE | CHEMBL53 | D2-like dopamine receptor agonist | AGONIST | ChEMBL |
Trials 2309
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07575516 | RISPERIDONE | PHASE2 | ClinicalTrials.gov | |
| NCT07565428 | ARIPIPRAZOLE | PHASE3 | ClinicalTrials.gov | |
| NCT07565428 | OLANZAPINE | PHASE3 | ClinicalTrials.gov | |
| NCT07565428 | RISPERIDONE | PHASE3 | ClinicalTrials.gov | |
| NCT07547384 | ARIPIPRAZOLE | ClinicalTrials.gov | ||
| NCT07541157 | RISPERIDONE | ClinicalTrials.gov | ||
| NCT07524868 | RISPERIDONE | ClinicalTrials.gov | ||
| NCT07523256 | RISPERIDONE | ClinicalTrials.gov | ||
| NCT07503002 | RISPERIDONE | PHASE1 | ClinicalTrials.gov | |
| NCT07493551 | PALIPERIDONE PALMITATE | ClinicalTrials.gov |
NIH grants 7939
NIH projects whose papers are about the gene, through NIH's grant-paper links.
| Project | Title | Its papers about the gene | Newest fiscal year | Source |
|---|---|---|---|---|
| R01MH054137 | Structure and Function of Dopamine Receptors | 67 | 2,025 | NIH's project files |
| ZIAAA000550 | Neurobiology of Drug Reward and Addiction | 67 | 2,025 | NIH's project files |
| ZIADA000493 | Functional and Pharmacological Significance of Receptor Heteromers in the CNS | 53 | 2,025 | NIH's project files |
| UL1TR001863 | Yale Clinical and Translational Science Award | 47 | 2,025 | NIH's project files |
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 42 | 2,025 | NIH's project files |
| ZIANS002263 | Molecular And Pharmacological Studies Of Dopamine Receptors | 34 | 2,025 | NIH's project files |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 29 | 2,025 | NIH's project files |
| ZIADA000606 | Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptor | 26 | 2,025 | NIH's project files |
| ZIADA000424 | Novel Dopamine D3/D2 Receptor Ligands | 23 | 2,025 | NIH's project files |
| P50AA012870 | Center for the Translational Neuroscience of Alcoholism | 19 | 2,025 | NIH's project files |
Papers 16048
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| PMID | Found by | Source |
|---|---|---|
| 42826505 | PubTator, text mining | PubMed |
| 42805551 | PubTator, text mining | PubMed |
| 42801895 | PubTator, text mining | PubMed |
| 42801338 | PubTator, text mining | PubMed |
| 42800225 | PubTator, text mining | PubMed |
| 42798706 | PubTator, text mining | PubMed |
| 42796507 | PubTator, text mining | PubMed |
| 42785810 | PubTator, text mining | PubMed |
| 42780122 | PubTator, text mining | PubMed |
| 42767220 | PubTator, text mining | PubMed |
Release gene-search-2026-11-11-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
HGNC: CC0: https://www.genenames.org/about/license/
NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH's project files and grant-paper links: Public domain (NIH RePORTER)
Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubTator 3: Public domain
UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license